Department of Animal Production-Ruminants, School of Veterinary Medicine, National Autonomous University of Mexico, Mexico City 04510, Mexico.
Department of Microbiology and Immunology, School of Veterinary Medicine, National Autonomous University of Mexico, Mexico City 04510, Mexico.
J Vet Sci. 2020 Nov;21(6):e87. doi: 10.4142/jvs.2020.21.e87.
A new, extended long-acting tilmicosin (TLAe) preparation was tested against intramammary ceftiofur (CEF) using a non-inferiority trial model during dry-cow therapy (DCT) in a farm with high bovine population density and deficient hygiene application.
To evaluate the possibility that TLAe administered parenterally can achieve non-inferiority status compared to CEF administered intramammary for DCT.
Cows were randomly assigned to TLAe (20 mg/kg subcutaneous; n = 53) or CEF (CEF-HCl, 125 mg/quarter; n = 38 cows) treatment groups. California mastitis testing, colony-forming unit assessment (CFU/mL), and number of cases positive for were quantified before DCT and 7 d after calving. A complete cure was defined as no bacteria isolated; partial cure when CFU/mL ranged from 150 to 700, and cure-failure when CFU/mL was above 700.
TLAe and CEF had overall cure rates of 57% and 53% ( > 0.05) and cure rates of 77.7% and 25%, respectively ( < 0.05). The pathogens detected at DCT and 7 days after calving were (62.71% and 35.55%), spp. (22.03% and 35.55%), (10.16% and 13.33%), and (5.08% and 15.55%). Non-inferiority and binary logistic regression analyses revealed a lack of difference in overall efficacies of TLAe and CEF. Apart from , was the predominant pathogen found in both groups.
This study is the first successful report of parenteral DCT showing comparable efficacy as CEF, the gold-standard. The extended long-term pharmacokinetic activity of TLAe explains these results.
在一个奶牛密度高且卫生应用不足的农场，使用非劣效性试验模型，对干奶期治疗（DCT）中新型长效替米考星（TLAe）制剂与乳房内头孢噻呋（CEF）进行了比较。
评估 TLAe 经皮给药相对于乳房内 CEF 给药用于 DCT 是否具有非劣效性。
将奶牛随机分配到 TLAe（20mg/kg 皮下；n=53）或 CEF（CEF-HCl，125mg/乳房；n=38 头奶牛）治疗组。在 DCT 前和产后 7d 时，对加利福尼亚乳房炎检测、集落形成单位评估（CFU/mL）和 阳性病例数进行量化。完全治愈定义为未分离出细菌；部分治愈时 CFU/mL 范围为 150 至 700，治愈失败时 CFU/mL 高于 700。
TLAe 和 CEF 的总体治愈率分别为 57%和 53%（>0.05）和 77.7%和 25%（<0.05）。在 DCT 和产后 7d 时检测到的病原体分别为 （62.71%和 35.55%）、 spp.（22.03%和 35.55%）、 （10.16%和 13.33%）和 （5.08%和 15.55%）。非劣效性和二项逻辑回归分析表明，TLAe 和 CEF 的总体疗效无差异。除 外， 是两组中主要的病原体。
本研究首次成功报告了与金标准 CEF 相比，经皮 DCT 具有相似的疗效。TLAe 的延长长效药代动力学活性解释了这些结果。
